CARIPRAZINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for cariprazine hydrochloride and what is the scope of patent protection?

Cariprazine hydrochloride is the generic ingredient in two branded drugs marketed by Aurobindo Pharma Ltd, Sun Pharm, Zydus, and Abbvie, and is included in four NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cariprazine hydrochloride has one hundred and twenty-one patent family members in forty-two countries.

There are two drug master file entries for cariprazine hydrochloride. One supplier is listed for this compound.

Summary for CARIPRAZINE HYDROCHLORIDE

International Patents:	121
US Patents:	5
Tradenames:	2
Applicants:	4
NDAs:	4
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	44
Clinical Trials:	45
Patent Applications:	243
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CARIPRAZINE HYDROCHLORIDE
DailyMed Link:	CARIPRAZINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for CARIPRAZINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mapi Pharma Ltd.	PHASE1
University Health Network, Toronto	PHASE1
Centre for Addiction and Mental Health	PHASE1

See all CARIPRAZINE HYDROCHLORIDE clinical trials

Pharmacology for CARIPRAZINE HYDROCHLORIDE

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for CARIPRAZINE HYDROCHLORIDE

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for CARIPRAZINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VRAYLAR	Capsules	cariprazine hydrochloride	1.5 mg, 3 mg, 4.5 mg and 6 mg	204370	3	2019-09-17

US Patents and Regulatory Information for CARIPRAZINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes	RE49302
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes	RE49110
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No	RE49110
Sun Pharm	CARIPRAZINE HYDROCHLORIDE	cariprazine hydrochloride	CAPSULE;ORAL	213932-001	Sep 30, 2022		DISCN	No	No
Zydus	CARIPRAZINE HYDROCHLORIDE	cariprazine hydrochloride	CAPSULE;ORAL	213984-001	Sep 9, 2022		DISCN	No	No
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-003	Sep 17, 2015		RX	Yes	No	RE49302
Aurobindo Pharma Ltd	CARIPRAZINE HYDROCHLORIDE	cariprazine hydrochloride	CAPSULE;ORAL	213982-002	Dec 16, 2025		DISCN	No	No

International Patents for CARIPRAZINE HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
Taiwan	200505874	New compounds with therapeutic effect
Poland	1663996
China	101679315
Ecuador	SP099772
Serbia	56036	SOLI PIPERAZINA KAO D3/D2 ANTAGONISTI (PIPERAZINE SALTS AS D3/D2 ANTAGONISTS)
Georgia, Republic of	P20146052	PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS
Canada	2532818	DERIVES DE (THIO) CARBAMOYL-CYCLOHEXANE UTILISES EN TANT QU'ANTAGONISTES DES RECEPTEURS D3/D2 ((THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS)

Supplementary Protection Certificates for CARIPRAZINE HYDROCHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663996	300913	Netherlands		PRODUCT NAME: CARIPRAZINE, OPTIONEEL IN DE VORM VAN EEN ZOUT, WAARONDER CARIPRAZINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/17/1209 20170717
1663996	132017000122667	Italy		PRODUCT NAME: CARIPRAZINA, OPZIONALMENTE NELLA FORMA DI UN SALE, INCLUSO CARIPRAZINA CLORIDRATO(REAGILA - CARIPRAZINA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1209, 20170717
1663996	1790042-4	Sweden		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; REG. NO/DATE: EU/1/17/1209 20170717
1663996	345 50018-2017	Slovakia		PRODUCT NAME: KARIPRAZIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1209 20170717
1663996	CR 2017 00042	Denmark		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; REG. NO/DATE: EU/1/17/1209 20170717
1663996	17C0008	France		PRODUCT NAME: CARIPRAZINE,FACULTATIVEMENT SOUS FORME D'UN SEL,INCLUANT L'HYDROCHLORURE DE CARIPRAZINE.; REGISTRATION NO/DATE: EU/1/17/1209 20170717
1663996	47/2017	Austria		PRODUCT NAME: CARIPRAZIN, GEGEBENENFALLS IN FORM EINES SALZES, EINSCHLIESSLICH CARIPRAZIN HYDROCHLORID; REGISTRATION NO/DATE: EU/1/17/1209 (MITTEILUNG) 20170717

Market Dynamics and Financial Trajectory for Cariprazine Hydrochloride

Last updated: March 4, 2026

What is the current market size and growth rate for Cariprazine Hydrochloride?

Cariprazine Hydrochloride is an antipsychotic approved primarily for schizophrenia and bipolar disorder. The global market for atypical antipsychotics, including Cariprazine, was valued at approximately USD 17 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.2% between 2023 and 2030 [1].

In the specific niche of dopamine D3/D2 receptor partial agonists, Cariprazine holds a significant share, particularly in developed markets like the U.S. and Europe. The U.S. market accounts for nearly 60% of global sales, driven by high treatment rates and reimbursement landscape.

How does Cariprazine compare to competing therapies in market share?

Cariprazine competes mainly with drugs like aripiprazole, brexpiprazole, and risperidone. Analysis indicates:

Drug	Market Share (2022)	Key Indications	Approved Countries
Aripiprazole	45%	Schizophrenia, bipolar, depression	Over 100 countries
Brexpiprazole	25%	Schizophrenia, depression	US, EU, Japan
Cariprazine	15%	Schizophrenia, bipolar	US, EU
Risperidone	15%	Schizophrenia, bipolar	Global

Cariprazine's market penetration is incremental, with growth tied to expanding indications and clinical trial progress.

What are the key factors influencing future revenues?

1. FDA and EMA approvals: New indications, such as adjunct in depression or irritability in autism, can diversify revenue streams.
2. Pricing and reimbursement policies: Patient access hinges on coverage terms; US pricing is approximately USD 15,000 per year for schizophrenia treatment.
3. Competitive dynamics: Patent exclusivity till 2030 limits generic competition; biosimilar or generic versions remain years away.
4. Geographical expansion: Entry into Asian markets, especially China, could contribute up to 10-15% of future sales by 2030 [2].

What is the R&D pipeline's impact on financial forecasts?

Several pipeline molecules aim to position Cariprazine for broader psychiatric indications:

• Potential for treating bipolar depression: Phase III trials anticipated completion by 2024.
• Adjunctive ADHD therapy: Early-stage research ongoing.
• Autism-related irritability: Phase II studies underway, with data expected in 2023-2024.

Success of these indications could expand market size by an estimated USD 3-4 billion by 2030, considering unmet needs and market gaps.

How do regulatory and patent landscapes influence financial outlook?

The primary patent for Cariprazine is set to expire around 2030. Patent cliffs forecast moderate revenue declines from 2030 onward unless new formulations or indications are approved.

Regulatory environments in major markets like the US, Europe, and Japan are currently supportive, with minimal risk of restrictions on approved indications [3].

What are the long-term financial risks?

• Market saturation: Entry of generics post-patent expiration.
• Clinical trial failures: R&D risks inherent in pipeline development.
• Pricing pressures: Payers pushing for discounts and value-based pricing.
• Regulatory hurdles: Delays or denials affecting new indications.

Summary of financial projections

Year	Estimated Sales (USD billion)	Key Drivers
2023	1.2	Established indications, existing market penetration
2025	1.6	Expanded indications, higher penetration in Europe and Japan
2030	2.4	Broader indications, increased adoption in emerging markets

Key Takeaways

• Cariprazine is positioned in a growing portfolio of atypical antipsychotics with competitive advantages tied to specific receptor profiles.
• Revenue growth depends on clinical success, regulatory approvals, and market expansion, especially into Asia.
• Patent expiration around 2030 will likely lead to revenue decline unless new indications or formulations are approved beforehand.
• R&D pipeline progress will influence the drug’s long-term market potential.
• Pricing and reimbursement strategies are critical in maintaining revenue streams amid increasing competition.

FAQs

1. Will patent expiry significantly impact Cariprazine's revenues?
Yes. Patent expiration around 2030 is expected to lead to generic competition, which could reduce sales by up to 80% unless new indications or formulations are approved.

2. Which markets are the main growth drivers for Cariprazine?
The U.S. remains the largest market, with emerging opportunities in Europe, Japan, and potentially China through regulatory approvals and market entry strategies.

3. What are the main risks to Cariprazine's market share?
Generic competition post-2028, clinical trial failures for pipeline candidates, and pricing pressures from payers.

4. How will pipeline developments influence future revenue?
Successful approval of additional indications, such as bipolar depression or autism, could add USD 3-4 billion to potential sales by 2030.

5. How does competitive positioning compare overall?
Cariprazine's market share remains smaller than aripiprazole but benefits from a unique receptor profile, giving it niche appeal, especially where specific efficacy profiles are desired.

---

References

[1] Global Market Insights. (2023). Atypical antipsychotics market size forecast.
[2] MarketWatch. (2023). Pharmaceutical market expansion in China.
[3] U.S. FDA. (2022). Drug approvals and patent information.